-
-
FDA Approves Roche's PI3Kα Inhibitor - Doubled PFS!
FDA
The FDA approved Genentech's PI3Kα inhibitor, Inavolisib (Itovebi), in combination with palbociclib and fulvestrant for advanced breast cancer patients with PIK3CA mutations. The therapy showed a significant 57% reduction in disease progression in the Phase III INAVO120 trial.
-
循化|
汶川县|
金华市|
泊头市|
织金县|
长葛市|
望都县|
三台县|
兴和县|
台山市|
南开区|
鄄城县|
台湾省|
建宁县|
攀枝花市|
嵊州市|
巴中市|
灵丘县|
襄城县|
工布江达县|
仁寿县|
辛集市|
广丰县|
重庆市|
苗栗县|
太仆寺旗|
商城县|
绵竹市|
海晏县|
健康|
讷河市|
胶州市|
余干县|
兴业县|
宜宾市|
永登县|
图木舒克市|
平和县|
宜丰县|
柘荣县|
涡阳县|